caa a22 4500 605490252 CHVBK 20210128100504.0 cr unu---uuuuu 210128e20150201xx s 000 0 eng 10.1007/s10147-014-0690-6 doi (NATIONALLICENCE)springer-10.1007/s10147-014-0690-6 Hypofractionated chemoradiotherapy with temozolomide as a treatment option for glioblastoma patients with poor prognostic features [Elektronische Daten] [Yu Lim, Il Kim, Tae Han, Seung Choi, Sung-Hye Park, Chul-Kee Park, Sun Paek, Se-Hoon Lee, Tae Kim] Background: Although the optimal treatment of frail glioblastoma patients is still controversial, previous randomized trials have excluded such patients. This study aimed to evaluate the feasibility and safety of hypofractionated radiotherapy (RT) with concomitant temozolomide for glioblastoma patients with poor prognostic features. Methods: We retrospectively reviewed 33 glioblastoma patients who underwent postoperative hypofractionated chemoradiotherapy. The patient criteria were either ≥70years or <70years with one or more risk factors: pre-RT performance status (ECOG score) ≥3, biopsy only, or rapid disease progression immediately after surgery. The median RT dose was 45Gy (range 30-45) with a fraction size of 3Gy. Results: The median age was 66.0years. Eighteen patients (55%) had poor pre-RT performance status (ECOG ≥3), and 16 patients (48%) underwent stereotactic biopsy only. The median overall survival (OS) and progression-free survival were 10.6 and 7.5months, respectively. Poor pre- and post-RT performance status [hazard ratio (HR) 3.12, 95% confidence interval (CI) 1.21-8.07 and HR 4.51, 95% CI 1.44-14.12, respectively] and no pseudoprogression (HR 5.43, 95% CI 1.58-18.61) were associated with poorer OS. While acute neurologic symptoms were reported in 5 patients (15%), toxicity profiles were acceptable without treatment-related aggravation of performance status. Conclusions: Concurrent chemoradiotherapy with temozolomide, the current standard treatment after surgery for glioblastoma, could be shortened without increasing side effects for patients with poor prognostic features. Japan Society of Clinical Oncology, 2014 Glioblastoma nationallicence Hypofractionated radiotherapy nationallicence Temozolomide nationallicence Poor performance status nationallicence Elderly nationallicence Lim Yu Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Republic of Korea aut Kim Il Department of Radiation Oncology, Cancer Research Institution, Institute of Radiation Medicine, Medical Research Center, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, 110-744, Seoul, Republic of Korea aut Han Tae Department of Radiation Oncology, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Republic of Korea aut Choi Seung Department of Radiology, Seoul National University College of Medicine, Seoul, Republic of Korea aut Park Sung-Hye Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea aut Park Chul-Kee Department of Neurosurgery, Seoul National University College of Medicine, Seoul, Republic of Korea aut Paek Sun Department of Neurosurgery, Seoul National University College of Medicine, Seoul, Republic of Korea aut Lee Se-Hoon Division of Medical Oncology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea aut Kim Tae Division of Medical Oncology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea aut International Journal of Clinical Oncology Springer Japan 20/1(2015-02-01), 21-28 1341-9625 20:1<21 2015 20 10147 https://doi.org/10.1007/s10147-014-0690-6 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10147-014-0690-6 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Lim Yu Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Republic of Korea aut NATIONALLICENCE 700 1- Kim Il Department of Radiation Oncology, Cancer Research Institution, Institute of Radiation Medicine, Medical Research Center, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, 110-744, Seoul, Republic of Korea aut NATIONALLICENCE 700 1- Han Tae Department of Radiation Oncology, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Republic of Korea aut NATIONALLICENCE 700 1- Choi Seung Department of Radiology, Seoul National University College of Medicine, Seoul, Republic of Korea aut NATIONALLICENCE 700 1- Park Sung-Hye Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea aut NATIONALLICENCE 700 1- Park Chul-Kee Department of Neurosurgery, Seoul National University College of Medicine, Seoul, Republic of Korea aut NATIONALLICENCE 700 1- Paek Sun Department of Neurosurgery, Seoul National University College of Medicine, Seoul, Republic of Korea aut NATIONALLICENCE 700 1- Lee Se-Hoon Division of Medical Oncology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea aut NATIONALLICENCE 700 1- Kim Tae Division of Medical Oncology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea aut NATIONALLICENCE 773 0- International Journal of Clinical Oncology Springer Japan 20/1(2015-02-01), 21-28 1341-9625 20:1<21 2015 20 10147